Quick Answer
Cardiol Therapeutics Inc. reported R&D Expense of $14.22 million for fiscal year 2023.
Cardiol Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $14.22M | -25.0% |
| 2022 | $18.96M | +74.4% |
| 2021 | $10.87M | +2.5% |
| 2020 | $10.60M | — |
- Cardiol Therapeutics Inc. showed a decrease of -25.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2023 period, Cardiol Therapeutics Inc.’s r&d expense has grown by 34.2% (from $10.60 million to $14.22 million).
- The most recent figure is from Cardiol Therapeutics Inc.’s fiscal year 2023 report (Form 20-F), filed with the SEC on April 1, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: